Repros’ Proellex Is Poised To Enter Phase III – Again
This article was originally published in Pharmaceutical Approvals Monthly
Telapristone was put on clinical hold due to liver toxicity, but the company’s pursuit of vaginal formulation and re-analysis of the initial oral studies allowed the oral program to resume.
You may also be interested in...
Most requests for the FDA’s less-heralded expedited review designation are based on Phase II or earlier data, and have a greater chance of success than requests for breakthrough designation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.